A total of 100 µg of protein from each sample was treated with 5 mU of O-glycosidase and 10 mU of sialidase.
Proteins (0.4 mg) were treated with 10 mU endoglycosidase H or 125 mU endoglycosidase F at 37°C for 16 h.
The effectiveness of interferon with 10 MU (ε1) and with 3 MU (ε2) were pair wise correlated (R = 0.8, P < 0.001).
By contrast, most of non-SVR treated with 3-MU regimen had histological worsening.
Cells were then lysed and immediately digested with 7.5 125 mU of MN.
Adjacent sections were incubated with 0 mU (control), 10 mU, 100 mU or 1000 mU alkaline phosphatase (Sigma, P4252) in Tris HCl buffer (100 mM Tris, pH 8.1 with 1% Triton X-100), at room temperature for 18 h prior to immunostaining as described (Sternberger and Sternberger, 1983).
All PCR products were sequenced to verify the mutation rate for all the new mutations and to get the mutant genes sequence for SPT15-Mu and TAF23-Mu.
Then, the library of mutations was constructed with that combination of genes SPT15-Mu and TAF23-Mu.
Gene sequencing of exons 15 21 of the c-Met TKD revealed no relevant mutations associated with SU11274 resistance in either parental or resistant MU and RU cell lines, and demonstrated 100% homology with the reference NCBI gene sequence (NM_000245).
Two MUs were located on the surface of hemoglobin forming a disulfide bond with β-Cys93 (MU-1/MU-1′; Figure 3B and Supporting Information Figure S3).
